A Feasibility Study of Mindfulness Training Transcranial Direct Current Stimulation (tDCS) in Adults With Overweight and Obesity (MINDED)

A Feasibility Study of Mindfulness Training Transcranial Direct Current Stimulation (tDCS) in Adults With Overweight and Obesity.

This study will investigate the feasibility of combining an app-based Mindfulness training (MT) with at-home administered transcranial direct current stimulation (tDCS) in adults with overweight or obesity and assess whether MT with tDCS may improve weight-related behaviours in this population. Specifically, the study will assess whether MT+ active tDCS, as opposed to MT+ sham tDCS or waiting list control, reduces high calorie food craving and consumption. Findings will inform the development of a future large-scale randomised controlled trial. The trial will be conducted in the UK.

Study Overview

• Status: Not yet recruiting
• Conditions: Adults With Overweight and Obesity
• Intervention / Treatment: Combination product: Mindfulness training + real tDCS; Combination product: Mindfulness training + sham tDCS

Detailed Description

A randomised controlled feasibility trial with three parallel arms: [MT + real tDCS] vs [MT + sham tDCS] vs [Waiting list control group].

• Study Type: Interventional
• Enrollment (Anticipated): 87
• Phase: Phase 4

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Right-handed adults aged 18 to 60 w
• Overweight or obese (BMI ≥25 kg/ m2) according to World Health Organisation (WHO) criteria.
• Use and understand English as a language for everyday conversation.
• Have access to a laptop or desktop computer with webcam and to able to attend baseline, post intervention and follow up assessments in the Institute of Psychiatry, Psychology and Neuroscience (KCL).

Exclusion Criteria:

• Insufficient written and spoken English
• All known contraindications to tDCS (Brunoni et al., 2012)
• Pregnancy; history of neurological disease and/or seizure
• Having any metallic implants in the head or body
• History of head or eye injury
• Significant health problems in the previous six months
• A lifetime diagnosis of substance dependence, psychosis, bipolar disorder, borderline personality disorder; any other primary psychiatric disorder requiring treatment in its own right
• Taking psychotropic medication
• Taking medication for weight loss Regular, current or past, mindfulness meditation or yoga practice (defined as > 20 minutes, twice or more per week during the past 2 months)
• Consuming more than 14 units of alcohol per week who are unwilling to reduce their alcohol intake for the duration of the treatment
• Current illicit drug use
• Learning difficulties that would preclude safe tDCS self-administration and/or completion of questionnaire measures and neurocognitive tasks (e.g.; working memory and inhibitory control)
• Current atypical anorexia nervosa or purging once a week or more.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: [Mindfulness training + real tDCS]	Combination product: Mindfulness training + real tDCS; The MT is an established app-based programme delivered by Headspace®. During MT, participants complete guided meditation sessions which focus on mindful eating and on coping with cravings. Each MT session lasts 15 min. Participants in the MT+ real tDCS and MT+ sham tDCS groups will be given instructions to practice daily mindfulness for 3 weeks. During 10 of these sessions, MT and real/sham tDCS will be delivered concurrently. TDCS: During tDCS, a constant weak direct current is applied via electrodes (anode and cathode) placed on the scalp. In this study, the anode will be placed over the right dorsolateral prefrontal cortex (dlPFC) and the cathode will be placed over the left dlPFC. In the real tDCS condition, stimulation will be delivered at a constant current of 2 mA with a 10 second fade in/fade out for 20 minutes. In sham tDCS, the stimulator will deliver 60 seconds of active stimulation at the start ("ramping up") and end ("ramping down") of the 20 minute period.
Placebo Comparator: [Mindfulness training + sham tDCS]	Combination product: Mindfulness training + sham tDCS; Mindfulness training + sham tDCS
No Intervention: [Waiting list control group].

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The feasibility of combining an app-based Mindfulness training (MT) with at-home Administered transcranial direct current stimulation (tDCS) by assessing intervention adherence	By assessing the tDCS session completed and the number of the MT sessions completed will be tracked through the app across the full 8 weeks	post treatment assessment (assessed at week 3 post start of treatment)
The feasibility of combining an app-based Mindfulness training (MT) with at-home Administered transcranial direct current stimulation (tDCS) by assessing intervention recruitment rate	Recruitment rate/month over months will be assessed to demonstrate that recruitment targets for the main trial can be met within an adequate time-frame.	post treatment assessment (assessed at week 3 post start of treatment)
The feasibility of combining an app-based Mindfulness training (MT) with at-home Administered transcranial direct current stimulation (tDCS) by assessing intervention retention rates	determine retention rates from randomization through intervention completion	post treatment assessment (assessed at week 3 post start of treatment) and at follow up (assessed at week 8 post start of treatment)
Participant views about treatment acceptability	Treatment Acceptability Questionnaire: asking participants to indicate if MT with self-administered tDCS is an acceptable approach to treatment and whether they would recommend MT + tDCS to a friend if they were struggling with their weight.	post treatment assessment (assessed at week 3 post start of treatment)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in high calorie food intake in the lab	Taste Test: actual food consumption will be measured by means of a bogus "taste test". Consumption will be determined by weighing the food before and after the "taste test" and the difference in weight from pre- to post-assessment will be converted into calories and used as a measure of food intake.	Baseline assessment, post treatment assessment (assessed at week 3 post start of treatment) and at follow up up (assessed at week 8 post start of treatment)
Change in food cravings	Food Cravings Questionnaire- Trait Version: it measures habitual experiences of food craving .	Baseline assessment, post treatment assessment (assessed at week 3 post start of treatment) and at follow up up (assessed at week 8 post start of treatment)
Change in weight loss using the bioelectrical impedance machine	Body Mass Index will be calculated measuring body weight and height (kg/m2) using a bioelectrical impedance machine (InBody S10).	Baseline assessment, post treatment assessment (assessed at week 3 post start of treatment) and at follow up up (assessed at week 8 post start of treatment)
Change in emotion regulation using Emotion Regulation Questionnaire	Emotion Regulation Questionnaire: A 10-item scale designed to measure respondents' tendency to regulate their emotions	Baseline assessment, post treatment assessment (assessed at week 3 post start of treatment) and at follow up up (assessed at week 8 post start of treatment)
Change in mood using the The Depression, Anxiety and Stress-Scale	The Depression, Anxiety and Stress-Scale: is a 21-item self-report questionnaire which evaluates mood, anxiety and stress levels over the previous week.	Baseline assessment, post treatment assessment (assessed at week 3 post start of treatment) and at follow up up (assessed at week 8 post start of treatment)
Change in working memory	Digital Span: the digit-span test for working memory is used to assess short-term memory. It has two subtests, the forward and backward tests.	Baseline assessment, post treatment assessment (assessed at week 3 post start of treatment) and at follow up up (assessed at week 8 post start of treatment)
Change in inhibitory control using the Go no Go Task	Go no Go Task: this task measures response inhibition. In the go/no-go task, participants respond to certain stimuli ("go" stimuli) and make no response for others ("no-go" stimuli). The main dependent measure in go/no-go tasks is the commission error rate (making a "go" response on "no-go" trials); fewer errors signify better response inhibition.	Baseline assessment, post treatment assessment (assessed at week 3 post start of treatment) and at follow up up (assessed at week 8 post start of treatment)
Change mindful eating-related outcomes	The Mindful Eating Questionnaire: is a 28-item questionnaire which will be used to assess awareness, distraction, disinhibition of eating and emotional and external eating. The	Baseline assessment, post treatment assessment (assessed at week 3 post start of treatment) and at follow up up (assessed at week 8 post start of treatment)
Change in high calorie food intake using the Short Food Frequency Questionnaire	Short Food Frequency Questionnaire: this has 25 food items and focuses on fruit, vegetables, fibre-rich foods, high fat and high-sugar foods, meat, meat products and fish. It provides an important method for determining variations in diet quality.	Baseline assessment, post treatment assessment (assessed at week 3 post start of treatment) and at follow up up (assessed at week 8 post start of treatment)
Change in food cravings using the Power of Food Scale	Power of Food Scale: this assesses the psychological influence of the presence or Availability of food. It measures appetite for, rather than consumption of, palatable foods at three levels of food proximity (food available, food present, and food tasted)	Baseline assessment, post treatment assessment (assessed at week 3 post start of treatment) and at follow up up (assessed at week 8 post start of treatment)
Change in Body composition	Body composition (primarily body fat percentage) will be assessed using a bioelectrical impedance machine (InBody S10).	Baseline assessment, post treatment assessment (assessed at week 3 post start of treatment) and at follow up up (assessed at week 8 post start of treatment)
Change in mood using Positive and Negative Affect Schedule	Positive and Negative Affect Schedule: this consists of two 10-item self-report scale which measures positive and negative affect.	Baseline assessment, post treatment assessment (assessed at week 3 post start of treatment) and at follow up up (assessed at week 8 post start of treatment)
Change in inhibitory control using Antisaccade task	Antisaccade task: this task measures participants' inhibitory attentional control performance under conditions that imposed a concurrent lower or heightened cognitive load. The task required participants to execute saccades towards (prosaccades), or saccades away from (antisaccades), a salient stimulus	Baseline assessment, post treatment assessment (assessed at week 3 post start of treatment) and at follow up up (assessed at week 8 post start of treatment)
Change in inhibitory control using Barrett Impulsiveness Scale	Barrett Impulsiveness Scale: this 30-item questionnaire during which participants are asked to reflect on a series of statements and indicate how frequently they apply to them.	Baseline assessment, post treatment assessment (assessed at week 3 post start of treatment) and at follow up up (assessed at week 8 post start of treatment)
Change in inhibitory control using Delayed Gratification Inventory	Delayed Gratification Inventory: this questionnaire assesses participants' ability/tendency to delay gratification.	Baseline assessment, post treatment assessment (assessed at week 3 post start of treatment) and at follow up up (assessed at week 8 post start of treatment)
Change in mindfulness outcomes	Mindful Awareness and Attention Scale: is a 15-item scale used to assess core characteristics of mindfulness	Baseline assessment, post treatment assessment (assessed at week 3 post start of treatment) and at follow up up (assessed at week 8 post start of treatment)
Eating Disorder Symptoms	The Eating Disorder Examination Questionnaire (EDE-Q) will be used to assess eating disorders symptoms. The EDE-Q is a 36-item self-report quesitonnaire, and a higher global score indicates more severe eating disorder symptoms.	Baseline assessment, post treatment assessment (assessed at week 3 post start of treatment) and at follow up up (assessed at week 8 post start of treatment)

Collaborators and Investigators

• Sponsor: King's College London

Study record dates

Study Major Dates

• Study Start (Anticipated): July 1, 2023
• Primary Completion (Anticipated): July 1, 2024
• Study Completion (Anticipated): October 1, 2024

Study Registration Dates

• First Submitted: April 11, 2023
• First Submitted That Met QC Criteria: May 9, 2023
• First Posted (Actual): May 19, 2023

Study Record Updates

• Last Update Posted (Actual): May 19, 2023
• Last Update Submitted That Met QC Criteria: May 9, 2023
• Last Verified: April 1, 2023

More Information

Terms related to this study

• Keywords: Mindfulness, Transcranial Direct Current Stimulation
• Additional Relevant MeSH Terms: Overnutrition; Nutrition Disorders; Body Weight; Obesity; Overweight
• Other Study ID Numbers: 3159550

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No